Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites

Olivia M. Dong; Megan C. Roberts; R. Ryanne Wu; Corrine I. Voils; Nina Sperber; Kara L. Gavin; Jill Bates; Catherine Chanfreau-Coffinier; Michael Naglich; Michael J. Kelley; Jason L. Vassy; Peruvemba Sriram; C. William Heise; Salvador Rivas; Maria Ribeiro; Jennifer G. Chapman; Deepak Voora

doi:10.2217/pgs-2021-0089

Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites

Olivia M. Dong, Megan C. Roberts, R. Ryanne Wu, Corrine I. Voils, Nina Sperber, Kara L. Gavin, Jill Bates, Catherine Chanfreau-Coffinier, Michael Naglich, Michael J. Kelley, Jason L. Vassy, Peruvemba Sriram, C. William Heise, Salvador Rivas, Maria Ribeiro, Jennifer G. Chapman, Deepak Voora

Internal Medicine, Phoenix

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Aim: The first Plan-Do-Study-Act cycle for the Veterans Affairs Pharmacogenomic Testing for Veterans pharmacogenomic clinical testing program is described. Materials & methods: Surveys evaluating implementation resources and processes were distributed to implementation teams, providers, laboratory and health informatics staff. Survey responses were mapped to the Consolidated Framework for Implementation Research constructs to identify implementation barriers. The Expert Recommendation for Implementing Change strategies were used to address implementation barriers. Results: Survey response rate was 23-73% across personnel groups at six Veterans Affairs sites. Nine Consolidated Framework for Implementation Research constructs were most salient implementation barriers. Program revisions addressed these barriers using the Expert Recommendation for Implementing Change strategies related to three domains. Conclusion: Beyond providing free pharmacogenomic testing, additional implementation barriers need to be addressed for improved program uptake.

Original language	English (US)
Pages (from-to)	1121-1133
Number of pages	13
Journal	Pharmacogenomics
Volume	22
Issue number	17
DOIs	https://doi.org/10.2217/pgs-2021-0089
State	Published - Nov 2021

Keywords

Plan-Do-Study-Act cycles
Veterans
Veterans Affairs
genetic testing
implementation barriers
pharmacogenomics
precision medicine
quality improvement

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.2217/pgs-2021-0089

Cite this

Dong, O. M., Roberts, M. C., Wu, R. R., Voils, C. I., Sperber, N., Gavin, K. L., Bates, J., Chanfreau-Coffinier, C., Naglich, M., Kelley, M. J., Vassy, J. L., Sriram, P., Heise, C. W., Rivas, S., Ribeiro, M., Chapman, J. G., & Voora, D. (2021). Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites. Pharmacogenomics, 22(17), 1121-1133. https://doi.org/10.2217/pgs-2021-0089

Dong, OM, Roberts, MC, Wu, RR, Voils, CI, Sperber, N, Gavin, KL, Bates, J, Chanfreau-Coffinier, C, Naglich, M, Kelley, MJ, Vassy, JL, Sriram, P, Heise, CW , Rivas, S, Ribeiro, M, Chapman, JG & Voora, D 2021, 'Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites', Pharmacogenomics, vol. 22, no. 17, pp. 1121-1133. https://doi.org/10.2217/pgs-2021-0089

@article{015bdd9ed7834bada4a979796f9705fb,

title = "Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites",

abstract = "Aim: The first Plan-Do-Study-Act cycle for the Veterans Affairs Pharmacogenomic Testing for Veterans pharmacogenomic clinical testing program is described. Materials & methods: Surveys evaluating implementation resources and processes were distributed to implementation teams, providers, laboratory and health informatics staff. Survey responses were mapped to the Consolidated Framework for Implementation Research constructs to identify implementation barriers. The Expert Recommendation for Implementing Change strategies were used to address implementation barriers. Results: Survey response rate was 23-73% across personnel groups at six Veterans Affairs sites. Nine Consolidated Framework for Implementation Research constructs were most salient implementation barriers. Program revisions addressed these barriers using the Expert Recommendation for Implementing Change strategies related to three domains. Conclusion: Beyond providing free pharmacogenomic testing, additional implementation barriers need to be addressed for improved program uptake.",

keywords = "Plan-Do-Study-Act cycles, Veterans, Veterans Affairs, genetic testing, implementation barriers, pharmacogenomics, precision medicine, quality improvement",

author = "Dong, {Olivia M.} and Roberts, {Megan C.} and Wu, {R. Ryanne} and Voils, {Corrine I.} and Nina Sperber and Gavin, {Kara L.} and Jill Bates and Catherine Chanfreau-Coffinier and Michael Naglich and Kelley, {Michael J.} and Vassy, {Jason L.} and Peruvemba Sriram and Heise, {C. William} and Salvador Rivas and Maria Ribeiro and Chapman, {Jennifer G.} and Deepak Voora",

note = "Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd.",

year = "2021",

month = nov,

doi = "10.2217/pgs-2021-0089",

language = "English (US)",

volume = "22",

pages = "1121--1133",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis Ltd.",

number = "17",

}

TY - JOUR

T1 - Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites

AU - Dong, Olivia M.

AU - Roberts, Megan C.

AU - Wu, R. Ryanne

AU - Voils, Corrine I.

AU - Sperber, Nina

AU - Gavin, Kara L.

AU - Bates, Jill

AU - Chanfreau-Coffinier, Catherine

AU - Naglich, Michael

AU - Kelley, Michael J.

AU - Vassy, Jason L.

AU - Sriram, Peruvemba

AU - Heise, C. William

AU - Rivas, Salvador

AU - Ribeiro, Maria

AU - Chapman, Jennifer G.

AU - Voora, Deepak

PY - 2021/11

Y1 - 2021/11

N2 - Aim: The first Plan-Do-Study-Act cycle for the Veterans Affairs Pharmacogenomic Testing for Veterans pharmacogenomic clinical testing program is described. Materials & methods: Surveys evaluating implementation resources and processes were distributed to implementation teams, providers, laboratory and health informatics staff. Survey responses were mapped to the Consolidated Framework for Implementation Research constructs to identify implementation barriers. The Expert Recommendation for Implementing Change strategies were used to address implementation barriers. Results: Survey response rate was 23-73% across personnel groups at six Veterans Affairs sites. Nine Consolidated Framework for Implementation Research constructs were most salient implementation barriers. Program revisions addressed these barriers using the Expert Recommendation for Implementing Change strategies related to three domains. Conclusion: Beyond providing free pharmacogenomic testing, additional implementation barriers need to be addressed for improved program uptake.

AB - Aim: The first Plan-Do-Study-Act cycle for the Veterans Affairs Pharmacogenomic Testing for Veterans pharmacogenomic clinical testing program is described. Materials & methods: Surveys evaluating implementation resources and processes were distributed to implementation teams, providers, laboratory and health informatics staff. Survey responses were mapped to the Consolidated Framework for Implementation Research constructs to identify implementation barriers. The Expert Recommendation for Implementing Change strategies were used to address implementation barriers. Results: Survey response rate was 23-73% across personnel groups at six Veterans Affairs sites. Nine Consolidated Framework for Implementation Research constructs were most salient implementation barriers. Program revisions addressed these barriers using the Expert Recommendation for Implementing Change strategies related to three domains. Conclusion: Beyond providing free pharmacogenomic testing, additional implementation barriers need to be addressed for improved program uptake.

KW - Plan-Do-Study-Act cycles

KW - Veterans

KW - Veterans Affairs

KW - genetic testing

KW - implementation barriers

KW - pharmacogenomics

KW - precision medicine

KW - quality improvement

UR - http://www.scopus.com/inward/record.url?scp=85119220078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119220078&partnerID=8YFLogxK

U2 - 10.2217/pgs-2021-0089

DO - 10.2217/pgs-2021-0089

M3 - Article

C2 - 34704830

AN - SCOPUS:85119220078

SN - 1462-2416

VL - 22

SP - 1121

EP - 1133

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 17

ER -

Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this